

# INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022



### [Registration No.197901003695 (47908-K)] INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

### UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

		Individual	Quarter	Year to	Date
			Preceding Year		Preceding Year
		<b>Current Year</b>	Corresponding	<b>Current Year to</b>	Corresponding
		Quarter	Quarter	Date	Period
	Note	31/03/2022	31/03/2021	31/03/2022	31/03/2021
		RM'000	RM'000	RM'000	RM'000
Revenue		223,298	240,532	223,298	240,532
Cost of sales		(119,289)	(141,363)	(119,289)	(141,363)
Gross profit	_	104,009	99,169	104,009	99,169
Other income		9,047	36,200	9,047	36,200
Selling and marketing expenses		(7,765)	(3,484)	(7,765)	(3,484)
Administrative expenses		(71,857)	(68,148)	(71,857)	(68,148)
Other expenses		(28,970)	(9,743)	(28,970)	(9,743)
Operating (loss)/profit	_	4,464	53,994	4,464	53,994
Finance income		2,316	911	2,316	911
Finance costs		(45,697)	(44,607)	(45,697)	(44,607)
Share of results of joint ventures		1,115	751	1,115	751
Share of results of an associate		2,300	8,293	2,300	8,293
(Loss)/profit before tax	_	(35,502)	19,342	(35,502)	19,342
Income tax	B5	10,257	(10,967)	10,257	(10,967)
(Loss)/profit for the period	_	(25,245)	8,375	(25,245)	8,375
Other comprehensive income to be reclassified to profit or loss in subsequent period:					
Foreign currency translation		117	90	117	90
Total comprehensive (loss)/income	_	(25,128)	8,465	(25,128)	8,465
(Loss)/profit attributable to:					
Owners of the parent		(33,394)	2,344	(33,394)	2,344
Holders of perpetual bond		8,626	4,281	8,626	4,281
Non-controlling interests		(477)	1,750	(477)	1,750
	_	(25,245)	8,375	(25,245)	8,375



### [Registration No.197901003695 (47908-K)] INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

### UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

		Individual Quarter		Year to Date	
		Current Year Quarter	Preceding Year Corresponding Quarter	Current Year to Date	Preceding Year Corresponding Period
	Note	31/03/2022	31/03/2021	31/03/2022	31/03/2021
		RM'000	RM'000	RM'000	RM'000
Total comprehensive (loss)/income attributable to:					
Owners of the parent		(33,277)	2,434	(33,277)	2,434
Holders of perpetual bond		8,626	4,281	8,626	4,281
Non-controlling interests		(477)	1,750	(477)	1,750
		(25,128)	8,465	(25,128)	8,465
(Loss)/earnings per share attributable to owners of the parent: (sen per share)					
- Basic	B10	(2.23)	0.16	(2.23)	0.16
- Diluted	B10	(1.38)	0.10	(1.38)	0.10



### INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

### UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

Not	As At e <u>31/03/2022</u> RM'000	As At 31/12/2021 RM'000
Assets		
Non-current assets	740 005	750,000
Property, plant and equipment	749,695	756,666
Biological assets Inventories	2,203 7,065,155	1,469 7,071,745
	• •	•
Investment properties Right-of-use assets	1,509,003 140,489	1,505,658 141,079
Investment in an associate	116,771	141,079
Investments in joint ventures	302,450	300,825
Other investments	302,430 887	887
Intangible assets	6,309	6,424
Deferred tax assets	223,925	150,665
Trade and other receivables	5,273	5,223
Trade and early receivables	10,122,160	10,055,112
		, ,
Current assets		
Biological assets	12	17
Inventories	599,831	566,007
Trade and other receivables	539,313	485,324
Contract cost assets	119,482	120,399
Contract assets	245,485	230,152
Tax recoverable	27,502	15,927
Other investments	157,189	166,700
Cash and bank balances	513,718	638,603
	2,202,532	2,223,129
Asset classified as held for sale	17,500	17,500
	2,220,032	2,240,629
Total assets	12,342,192	12,295,741



### INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

### **UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION**

	Note	As At <u>31/03/2022</u> RM'000	As At <u>31/12/2021</u> RM'000
Equity and liabilities			
Equity attributable to owners of the parent		0.420.500	0.046.460
Share capital  Irredeemable convertible preference shares		2,132,568 918,193	2,046,168 1,004,593
Treasury shares		(26,263)	(26,103)
Other reserves		1,555,475	1,611,486
Other reserves		4,579,973	4,636,144
Perpetual bond		519,067	527,791
Non-controlling interests		837,539	820,182
Total equity		5,936,579	5,984,117
• •			
Non-current liabilities  Deferred tax liabilities		568,534	507,147
Borrowings	B7	3,330,160	3,371,167
Trade and other payables		513,165	516,818
Irredeemable convertible preference shares		159,429	164,193
Contract liabilities		136,059	133,206
Lease liabilities		8,618	5,609
		4,715,965	4,698,140
Current liabilities			
Borrowings	В7	548,814	544,636
Trade and other payables		1,046,800	1,000,254
Irredeemable convertible preference shares		10,009	9,814
Contract liabilities		68,493	47,216
Tax payable		12,320	8,340
Lease liabilities		3,212	3,224
25055 1105111055		1,689,648	1,613,484
Total liabilities	_	6,405,613	6,311,624
Total equity and liabilities		12,342,192	12,295,741
Net assets per share (RM)	_	3.02	3.21

The condensed consolidated statements of financial position should be read in conjunction with the audited financial statements for the financial year ended 31 December 2021 and the accompanying explanatory notes attached to the interim financial statements.



#### INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

#### UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

Attributable to owners of the parent <--Non-distributable--> Distributable Irredeemable Foreign Convertible Currency Treasury Share Preference Translation Retained Total Perpetual Non-controlling Total Earnings Shares Capital Shares Reserve Reserves Total Bond Interests Equity RM'000 As at 1 January 2021 2,044,322 1,004,593 (6,882)(109)1,664,257 1,664,148 4,706,181 252,613 800,512 5,759,306 Total comprehensive income 90 2,344 2,434 2,434 1,750 4,184 Distribution for the financial period 4,281 4,281 Distribution paid for the financial period (8,609)(8,609)Transaction with owners: Purchase of treasury shares (4,549)(4,549)(4,549)Total transaction with owners (4,549)(4,549)(4,549)As at 31 March 2021 2,044,322 1,004,593 (11,431) (19)1,666,601 1,666,582 4,704,066 248,285 802,262 5,754,613 As at 1 January 2022 2,046,168 1,004,593 (26,103)156 1,611,330 1,611,486 4,636,144 527,791 820,182 5,984,117 Total comprehensive income/(loss) (33,277)(33,754)117 (33,394)(33,277)(477)Distribution for the financial period 8,626 8,626 Distribution paid for the financial period (17,350)(17,350)Transactions with owners: (22,734)(22,734)17,834 (4,900) Acquisition of non-controlling interests (22,734)Conversion of irredeemable convertible preference shares to ordinary shares 86,400 (86,400)Purchase of treasury shares (160)(160)(160)(5,060) Total transactions with owners 86.400 (86,400) (22,734)(22,734)(22,894)17,834 (160)As at 31 March 2022 2,132,568 918,193 (26,263) 273 1,555,202 1,555,475 4,579,973 519,067 837,539 5,936,579

The condensed consolidated statement of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 31 December 2021 and the accompanying explanatory notes attached to the interim financial statements.



### INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

### UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Cash flows from operating activities         RM000         RM000           (Loss) (Loss) (profit before tax         (35,502)         19,342           Adjustments for:         Bepreciation of property, plant and equipment         8,691         7,694           Depreciation of right-of-use assets         1,412         1,023           Amortisation of intangible assets         115         115           Finance income         (2,316)         (911)           Finance costs         45,697         44,607           Share of results of an associate         (2,2300)         (8,293)           Share of results of joint ventures         (1,115)         (751)           Net gain on disposal of quoted shares         (22,848)         (12,397)           Fair value loss on quoted shares         (534)         (2,835)           Property, plant and equipment written off         3         6           Amortisation of security retainers accumulation fund         3         3           Amortisation of security retainers accumulation fund         (54)         (26)           Operating profit before working capital changes         18,445         52,138           Changes in working capital changes         (54,000)         (158,930)           Contract assets         (55,000)         (58,930)			
Cash flows from operating activities         (Loss)/profit before lax         (35,502)         19,342           Adjustments for:         1         1           Depreciation of property, plant and equipment         8,691         7,694           Depreciation of right-of-use assets         1,412         1,023           Amortisation of inlangible assets         115         115           Finance income         (2,316)         (911)           Finance costs         45,697         44,607           Share of results of an associate         (2,300)         (8,293)           Share of results of joint ventures         (1,115)         (751)           Net gain on disposal of quoted shares         (28,46)         (12,937)           Fair value loss on quoted shares         (28,167)         6,184           Dividend income on quoted shares         (534)         (2,835)           Property, plant and equipment written off         360         -           Amortisation of decrered license fees         (1,380)         (1,139)           Amortisation of security retainers accumulation fund         (54)         (26)           Operating profit before working capital changes         (54,000)         (158,930)           Changes in working capital         (54,000)         (158,930) <tr< th=""><th></th><th>31/03/2022</th><th>31/03/2021</th></tr<>		31/03/2022	31/03/2021
Closs)/profit before tax		RM'000	RM'000
Adjustments for.         Bepreciation of property, plant and equipment         8,691         7,694           Depreciation of right-of-use assets         1,412         1,023           Amortisation of intangible assets         115         115           Finance income         (2,316)         (911)           Finance costs         45,697         44,607           Share of results of an associate         (2,300)         (8,293)           Share of results of joint ventures         (1,115)         (751)           Net gain on disposal of quoted shares         (22,848)         (12,937)           Fair value loss on quoted shares         28,167         6,184           Dividend income on quoted shares         (354)         (2,835)           Property, plant and equipment written off         360         -           Amortisation of security retainers accumulation fund         3         3           Amortisation of security retainers accumulation fund         3         46           Unrealised returns on security retainers accumulation fund         (54)         (26)           Operating profit before working capital changes         (8,400)         (158,930)           Changes in working capital:         1         46         -           Trade and other receivables         (54,000)	· · ·		
Depreciation of property, plant and equipment         8,691         7,694           Depreciation of property, plant and equipment         1,412         1,023           Amortisation of intangible assets         1,15         115           Finance income         (2,316)         (911)           Finance costs         45,697         44,607           Share of results of joint ventures         (1,115)         (751)           Net gain on disposal of quoted shares         (22,048)         (12,937)           Fair value loss on quoted shares         28,167         6,184           Dividend income on quoted shares         (334)         (2,835)           Property, plant and equipment written off         3         62           Right-of-use assets written off         3         62           Right-of-use assets written off         3         6           Amortisation of deferred license fees         (1,380)         (1,389)           Amortisation of security retainers accumulation fund         3         3           Fair value loss on biological assets         46         -           Unrealised returns on security retainers accumulation fund         (54)         (26)           Operating profit before working capital:         (54)         (26)           Charriage and other receiv	` ',:	(35,502)	19,342
Depreciation of right-of-use assets         1,412         1,023           Amortisation of intangible assets         115         115           Finance income         (2,316)         (911)           Finance costs         45,697         44,607           Share of results of an associate         (2,300)         (8,293)           Share of results of joint ventures         (1,115)         (751)           Net gain on disposal of quoted shares         (22,248)         (12,937)           Fair value loss on quoted shares         28,167         6,184           Dividend income on quoted shares         (8,34)         (2,835)           Property, plant and equipment written off         3         62           Right-of-use assets written off         360         -           Amortisation of security retainers accumulation fund         3         3           Amortisation of security retainers accumulation fund         (54)         (26)           Operating profit before working capital changes         18,445         52,138           Changes in working capital.         (54)         (26)           Operating profit before working capital changes         (54,000)         (158,930)           Contract assets         (15,333)         (13,504)           Changes in working capital.	•		
Amortisation of intangible assets         115         115           Finance income         (2,316)         (911)           Finance cots         45,697         44,607           Share of results of an associate         (2,300)         (8,293)           Share of results of joint ventures         (1,115)         (751)           Net gain on disposal of quoted shares         (22,848)         (12,937)           Fair value loss on quoted shares         (34)         (2,835)           Property, plant and equipment written off         3 60         -           Amortisation of security retainers accumulation fund         3 60         -           Amortisation of security retainers accumulation fund         3 3         3           Fair value loss on biological assets         46         -           Unrealised returns on security retainers accumulation fund         (54)         (26)           Operating profit before working capital:         18,445         52,138           Changes in working capital:         18,445         52,138           Contract assets         (54,000)         (158,930)           Contract cost assets         (54,000)         (158,930)           Contract liabilities         3,257         2,746           Biological assets         (775)		· · · · · · · · · · · · · · · · · · ·	
Finance income         (2,316)         (911)           Finance costs         45,697         44,607           Share of results of joint ventures         (1,115)         (751)           Net gain on disposal of quoted shares         (22,848)         (12,937)           Fair value loss on quoted shares         (28,167)         6,184           Dividend income on quoted shares         (534)         (2,835)           Property, plant and equipment written off         3         62           Right-of-use assets written off         360         -           Amortisation of deferred license fees         (1,380)         (1,139)           Amortisation of security retainers accumulation fund         3         3           Unrealised returns on security retainers accumulation fund         (54)         (26)           Operating profit before working capital changes         18,445         52,138           Changes in working capital:         3         45           Trade and other receivables         (54,000)         (158,930)           Contract assets         (15,333)         (13,504)           Inventories         (4,715)         (30,034)           Contract diabilities         3,257         2,746           Biological assets         (775)         - <td>·</td> <td>•</td> <td></td>	·	•	
Finance costs         45,697         44,607           Share of results of joint ventures         (2,300)         (8,293)           Share of results of joint ventures         (1,115)         (751)           Net gain on disposal of quoted shares         (22,848)         (12,937)           Fair value loss on quoted shares         (534)         (2,835)           Property, plant and equipment written off         3         62           Right-of-use assets written off         360         -           Amortisation of deferred license fees         (1,380)         (1,139)           Amortisation of security retainers accumulation fund         3         3           Fair value loss on biological assets         46         -           Unrealised returns on security retainers accumulation fund         (54)         (26)           Operating profit before working capital changes         18,445         52,138           Changes in working capital:         (54,000)         (158,930)           Trade and other receivables         (54,000)         (158,930)           Contract assets         (54,000)         (158,930)           Inventories         (54,000)         (158,930)           Contract liabilities         3,257         2,746           Biological assets         (775)	· · · · · · · · · · · · · · · · · · ·		
Share of results of an associate         (2,300)         (6,293)           Share of results of joint ventures         (1,115)         (751)           Net gain on disposal of quoted shares         (22,848)         (12,937)           Fair value loss on quoted shares         28,167         6,184           Dividend income on quoted shares         (534)         (2,835)           Property, plant and equipment written off         3         62           Right-of-use assets written off         360         -           Amortisation of deferred license fees         (1,380)         (1,139)           Amortisation of security retainers accumulation fund         3         3           Fair value loss on biological assets         46         -           Unrealised returns on security retainers accumulation fund         (54)         (26)           Operating profit before working capital:         (54)         (26)           Trade and other receivables         (54,000)         (158,930)           Contract assets         (54,000)         (158,930)           Contract assets         (54,000)         (158,930)           Contract disabilities         3,257         2,746           Biological assets         (775)         -           Trade and other payables         60,023 <td></td> <td>· · · · ·</td> <td>` '</td>		· · · · ·	` '
Share of results of joint ventures         (1,115)         (751)           Net gain on disposal of quoted shares         (22,848)         (12,937)           Fair value loss on quoted shares         28,167         6,184           Dividend income on quoted shares         (534)         (2,835)           Property, plant and equipment written off         360         -           Right-of-use assets written off         360         -           Amortisation of deferred license fees         (1,380)         (1,139)           Amortisation of security retainers accumulation fund         3         3           Fair value loss on biological assets         46         -           Unrealised returns on security retainers accumulation fund         (54)         (26)           Operating profit before working capital changes         18,445         52,138           Changes in working capital:         18,445         52,138           Changes in working capital changes         (54,000)         (158,930)           Contract assets         (15,333)         (13,504)           Inventories         (54,000)         (158,930)           Contract cost assets         (21,602)         36,917           Contract liabilities         3,257         2,746           Biological assets <th< td=""><td></td><td></td><td></td></th<>			
Net gain on disposal of quoted shares         (22,848)         (12,937)           Fair value loss on quoted shares         28,167         6,184           Dividend income on quoted shares         (534)         (2,835)           Property, plant and equipment written off         3         62           Right-of-use assets written off         360         -           Amortisation of deferred license fees         (1,380)         (1,139)           Amortisation of security retainers accumulation fund         3         3           Fair value loss on biological assets         46         -           Unrealised returns on security retainers accumulation fund         (54)         (26)           Operating profit before working capital changes         18,445         52,138           Changes in working capital:         (54,000)         (158,930)           Contract assets         (54,000)         (158,930)           Contract assets         (54,000)         (158,930)           Contract cost assets         (54,000)         (158,930)           Contract liabilities         3,257         2,746           Biological assets         (775)			, ,
Fair value loss on quoted shares         28,167         6,184           Dividend income on quoted shares         (534)         (2,835)           Property, plant and equipment written off         360         -           Right-of-use assets written off         360         -           Amortisation of deferred license fees         (1,380)         (1,139)           Amortisation of security retainers accumulation fund         3         3           Fair value loss on biological assets         46         -           Unrealised returns on security retainers accumulation fund         (54)         (26)           Operating profit before working capital changes         18,445         52,138           Changes in working capital:         (54,000)         (158,930)           Contract assets         (54,000)         (158,930)           Contract cost assets         (15,333)         (13,504)           Inventories         (4,715)         (30,034)           Contract liabilities         3,257         2,746           Biological assets         (775)         -           Contract liabilities         3,257         2,746           Biological assets         (775)         -           Crotract liabilities         3,257         2,746 <td< td=""><td>•</td><td></td><td>, ,</td></td<>	•		, ,
Dividend income on quoted shares         (534)         (2,835)           Property, plant and equipment written off         3         62           Right-of-use assets written off         360         -           Amortisation of deferred license fees         (1,380)         (1,139)           Amortisation of security retainers accumulation fund         3         3           Fair value loss on biological assets         46         -           Urrealised returns on security retainers accumulation fund         (54)         (26)           Operating profit before working capital changes         18,445         52,138           Changes in working capital:         -         -           Trade and other receivables         (54,000)         (158,930)           Contract assets         (15,333)         (13,504)           Inventories         (4,715)         (30,034)           Contract cost assets         (21,602)         36,917           Contract disabilities         3,257         2,746           Biological assets         (775)         -           Trade and other payables         60,023         89,537           Cash used in operations         (14,700)         (21,130)           Finance costs paid         (30,002)         (52,957)	· · ·	• • •	, ,
Property, plant and equipment written off         3         62           Right-of-use assets written off         360         -           Amortisation of deferred license fees         (1,380)         (1,139)           Amortisation of security retainers accumulation fund         3         3           Fair value loss on biological assets         46         -           Unrealised returns on security retainers accumulation fund         (54)         (26)           Operating profit before working capital:         18,445         52,138           Changes in working capital:         (54,000)         (158,930)           Contract assets         (15,333)         (13,504)           Inventories         (4,715)         (30,034)           Contract cost assets         (21,602)         36,917           Contract diabilities         3,257         2,746           Biological assets         (775)         -           Trade and other payables         60,023         89,537           Cash used in operations         (14,700)         (21,130)           Finance costs paid         (38,635)         (45,215)           Net taxes paid         (38,635)         (45,215)           Net taxes paid         (30,000)         (25,957)           Net cash us	•	28,167	
Right-of-use assets written off         360         -           Amortisation of deferred license fees         (1,380)         (1,139)           Amortisation of security retainers accumulation fund         3         3           Fair value loss on biological assets         46         -           Unrealised returns on security retainers accumulation fund         (54)         (26)           Operating profit before working capital changes         18,445         52,138           Changes in working capital:         -         2,138           Trade and other receivables         (54,000)         (158,930)           Contract assets         (54,000)         (158,930)           Contract cost assets         (15,333)         (13,504)           Inventories         (4,715)         (30,034)           Contract cost assets         (21,602)         36,917           Contract liabilities         3,257         2,746           Biological assets         (775)         -           Trade and other payables         60,023         89,537           Cash used in operations         (14,700)         (21,130)           Pinance costs paid         (3,8635)         (45,215)           Net cash used in operating activities         (62,545)         (92,302) <t< td=""><td>·</td><td>(534)</td><td>(2,835)</td></t<>	·	(534)	(2,835)
Amortisation of deferred license fees         (1,380)         (1,139)           Amortisation of security retainers accumulation fund         3         3           Fair value loss on biological assets         46         -           Unrealised returns on security retainers accumulation fund         (54)         (26)           Operating profit before working capital:         18,445         52,138           Changes in working capital:         -         -           Trade and other receivables         (54,000)         (158,930)           Contract assets         (15,333)         (13,504)           Inventories         (4,715)         (30,034)           Contract cost assets         (21,602)         36,917           Contract liabilities         3,257         2,746           Biological assets         (7775)         -           Trade and other payables         60,023         89,537           Cash used in operations         (14,700)         (21,130)           Finance costs paid         (38,635)         (45,215)           Net taxes paid         (38,635)         (45,215)           Net taxes paid         (32,545)         (92,302)           Cash flows from investing activities         (25,957)           Purchase of property, plant and eq		3	62
Amortisation of security retainers accumulation fund         3         3           Fair value loss on biological assets         46         -           Unrealised returns on security retainers accumulation fund         (54)         (26)           Operating profit before working capital changes         18,445         52,138           Changes in working capital:         -           Trade and other receivables         (54,000)         (158,930)           Contract assets         (15,333)         (13,504)           Inventories         (4,715)         (30,034)           Contract cost assets         (21,602)         36,917           Contract liabilities         3,257         2,746           Biological assets         (775)         -           Trade and other payables         60,023         89,537           Cash used in operations         (14,700)         (21,130)           Finance costs paid         (38,635)         (45,215)           Net taxes paid         (38,635)         (45,215)           Net taxes paid         (9,210)         (25,957)           Net cash used in operating activities         (21,302)           Purchase of property, plant and equipment         (1,722)         (6,288)           Purchase of investment properties	· ·		-
Fair value loss on biological assets         46         -           Unrealised returns on security retainers accumulation fund         (54)         (26)           Operating profit before working capital changes         18,445         52,138           Changes in working capital:         Trade and other receivables         (54,000)         (158,930)           Contract assets         (15,333)         (13,504)           Inventories         (4,715)         (30,034)           Contract cost assets         (21,602)         36,917           Contract liabilities         3,257         2,746           Biological assets         (775)         -           Trade and other payables         60,023         89,537           Cash used in operations         114,700)         (21,130)           Finance costs paid         (38,635)         (45,215)           Net taxes paid         (8,25)         (25,957)           Net cash used in operating activities         (62,545)         (92,10)         (25,957)           Net cash used in operating activities         (62,545)         (92,302)           Cash flows from investing activities         (62,545)         (92,302)           Cash flows from investing activities         (1,722)         (6,288)           Pur		(1,380)	(1,139)
Unrealised returns on security retainers accumulation fund         (54)         (26)           Operating profit before working capital changes         18,445         52,138           Changes in working capital:         Trade and other receivables         (54,000)         (158,930)           Contract assets         (15,333)         (13,504)         (19,003)           Inventories         (4,715)         (30,034)           Contract cost assets         (21,602)         36,917           Contract liabilities         3,257         2,746           Biological assets         (775)         -           Trade and other payables         60,023         89,537           Cash used in operations         (14,700)         (21,130)           Finance costs paid         (38,635)         (45,215)           Net taxes paid         (38,635)         (45,215)           Net cash used in operating activities         (62,545)         (92,302)           Cash flows from investing activities         (62,545)         (92,302)           Cash flows from investing activities         (1,722)         (6,288)           Purchase of property, plant and equipment         (1,722)         (6,288)           Purchase of investment properties         (3,345)         (1,718)	Amortisation of security retainers accumulation fund	3	3
Operating profit before working capital changes         18,445         52,138           Changes in working capital:         52,138           Trade and other receivables         (54,000)         (158,930)           Contract assets         (15,333)         (13,504)           Inventories         (4,715)         (30,034)           Contract cost assets         (21,602)         36,917           Contract liabilities         3,257         2,746           Biological assets         (7775)         -           Trade and other payables         60,023         89,537           Cash used in operations         (14,700)         (21,130)           Finance costs paid         (38,635)         (45,215)           Net taxes paid         (9,210)         (25,957)           Net cash used in operating activities         (62,545)         (92,302)           Cash flows from investing activities         (62,545)         (92,302)           Cash flows from investing activities         (1,722)         (6,288)           Purchase of property, plant and equipment         (1,722)         (6,288)           Purchase of investment properties         (3,345)         (1,718)           Addition of right-of-use assets         (1,181)         (495)           Proceeds	Fair value loss on biological assets	46	-
Changes in working capital:         (54,000)         (158,930)           Contract assets         (15,333)         (13,504)           Inventories         (4,715)         (30,034)           Contract cost assets         (21,602)         36,917           Contract liabilities         3,257         2,746           Biological assets         (775)         -           Trade and other payables         60,023         89,537           Cash used in operations         (14,700)         (21,130)           Finance costs paid         (38,635)         (45,215)           Net taxes paid         (9,210)         (25,957)           Net cash used in operating activities         (62,545)         (92,302)           Cash flows from investing activities         (1,722)         (6,288)           Purchase of property, plant and equipment         (1,722)         (6,288)           Purchase of investment properties         (3,345)         (1,718)           Addition of right-of-use assets         (1,181)         (495)	Unrealised returns on security retainers accumulation fund	(54)	(26)
Trade and other receivables         (54,000)         (158,930)           Contract assets         (15,333)         (13,504)           Inventories         (4,715)         (30,034)           Contract cost assets         (21,602)         36,917           Contract liabilities         3,257         2,746           Biological assets         (775)         -           Trade and other payables         60,023         89,537           Cash used in operations         (14,700)         (21,130)           Finance costs paid         (38,635)         (45,215)           Net taxes paid         (9,210)         (25,957)           Net cash used in operating activities         (62,545)         (92,302)           Cash flows from investing activities         Value         (62,545)         (92,302)           Cash flows from investing activities         Value         (62,288)         (71,718)         (495)           Purchase of property, plant and equipment         (1,722)         (6,288)         (1,718)         (495)           Proceeds from disposal of quoted shares         (1,181)         (495)         (495)         (494)         (494)         (494)         (494)         (494)         (494)         (494)         (494)         (494)         (494)	Operating profit before working capital changes	18,445	52,138
Contract assets         (15,333)         (13,504)           Inventories         (4,715)         (30,034)           Contract cost assets         (21,602)         36,917           Contract liabilities         3,257         2,746           Biological assets         (775)         -           Trade and other payables         60,023         89,537           Cash used in operations         (14,700)         (21,130)           Finance costs paid         (38,635)         (45,215)           Net taxes paid         (9,210)         (25,957)           Net cash used in operating activities         (62,545)         (92,302)           Cash flows from investing activities         (62,545)         (92,302)           Cash flows from investing activities         (1,722)         (6,288)           Purchase of property, plant and equipment         (1,722)         (6,288)           Purchase of investment properties         (3,345)         (1,718)           Addition of right-of-use assets         (1,181)         (495)           Proceeds from disposal of quoted shares         40,046         49,497           Proceeds from disposal of property, plant and equipment         -         23           Acquisition of quoted shares         (35,854)         (25,395)     <	Changes in working capital:		
Inventories         (4,715)         (30,034)           Contract cost assets         (21,602)         36,917           Contract liabilities         3,257         2,746           Biological assets         (775)         -           Trade and other payables         60,023         89,537           Cash used in operations         (14,700)         (21,130)           Finance costs paid         (38,635)         (45,215)           Net taxes paid         (9,210)         (25,957)           Net cash used in operating activities         (62,545)         (92,302)           Cash flows from investing activities         (1,722)         (6,288)           Purchase of property, plant and equipment         (1,722)         (6,288)           Purchase of investment properties         (3,345)         (1,718)           Addition of right-of-use assets         (1,181)         (495)           Proceeds from disposal of quoted shares         40,046         49,497           Proceeds from disposal of property, plant and equipment         -         23           Acquisition of quoted shares         (35,854)         (25,395)           Dividend income received         534         2,835           Finance income received         2,316         911	Trade and other receivables	(54,000)	(158,930)
Contract cost assets         (21,602)         36,917           Contract liabilities         3,257         2,746           Biological assets         (775)         -           Trade and other payables         60,023         89,537           Cash used in operations         (14,700)         (21,130)           Finance costs paid         (38,635)         (45,215)           Net taxes paid         (9,210)         (25,957)           Net cash used in operating activities         (62,545)         (92,302)           Cash flows from investing activities         V         (6,288)           Purchase of property, plant and equipment         (1,722)         (6,288)           Purchase of investment properties         (3,345)         (1,718)           Addition of right-of-use assets         (1,181)         (495)           Proceeds from disposal of quoted shares         40,046         49,497           Proceeds from disposal of property, plant and equipment         -         23           Acquisition of quoted shares         (35,854)         (25,395)           Dividend income received         534         2,835           Finance income received         2,316         911	Contract assets	(15,333)	(13,504)
Contract liabilities         3,257         2,746           Biological assets         (775)         -           Trade and other payables         60,023         89,537           Cash used in operations         (14,700)         (21,130)           Finance costs paid         (38,635)         (45,215)           Net taxes paid         (9,210)         (25,957)           Net cash used in operating activities         (62,545)         (92,302)           Cash flows from investing activities         **         **           Purchase of property, plant and equipment         (1,722)         (6,288)           Purchase of investment properties         (3,345)         (1,718)           Addition of right-of-use assets         (1,181)         (495)           Proceeds from disposal of quoted shares         40,046         49,497           Proceeds from disposal of property, plant and equipment         -         23           Acquisition of quoted shares         (35,854)         (25,395)           Dividend income received         534         2,835           Finance income received         2,316         911	Inventories	(4,715)	(30,034)
Biological assets         (775)         -           Trade and other payables         60,023         89,537           Cash used in operations         (14,700)         (21,130)           Finance costs paid         (38,635)         (45,215)           Net taxes paid         (9,210)         (25,957)           Net cash used in operating activities         (62,545)         (92,302)           Cash flows from investing activities         (1,722)         (6,288)           Purchase of property, plant and equipment         (1,722)         (6,288)           Purchase of investment properties         (3,345)         (1,718)           Addition of right-of-use assets         (1,181)         (495)           Proceeds from disposal of quoted shares         40,046         49,497           Proceeds from disposal of property, plant and equipment         -         23           Acquisition of quoted shares         (35,854)         (25,395)           Dividend income received         534         2,835           Finance income received         2,316         911	Contract cost assets	(21,602)	36,917
Trade and other payables         60,023         89,537           Cash used in operations         (14,700)         (21,130)           Finance costs paid         (38,635)         (45,215)           Net taxes paid         (9,210)         (25,957)           Net cash used in operating activities         (62,545)         (92,302)           Cash flows from investing activities         (1,722)         (6,288)           Purchase of property, plant and equipment         (1,722)         (6,288)           Purchase of investment properties         (3,345)         (1,718)           Addition of right-of-use assets         (1,181)         (495)           Proceeds from disposal of quoted shares         40,046         49,497           Proceeds from disposal of property, plant and equipment         -         23           Acquisition of quoted shares         (35,854)         (25,395)           Dividend income received         534         2,835           Finance income received         2,316         911	Contract liabilities	3,257	2,746
Cash used in operations         (14,700)         (21,130)           Finance costs paid         (38,635)         (45,215)           Net taxes paid         (9,210)         (25,957)           Net cash used in operating activities         (62,545)         (92,302)           Cash flows from investing activities         (1,722)         (6,288)           Purchase of property, plant and equipment         (1,722)         (6,288)           Purchase of investment properties         (3,345)         (1,718)           Addition of right-of-use assets         (1,181)         (495)           Proceeds from disposal of quoted shares         40,046         49,497           Proceeds from disposal of property, plant and equipment         -         23           Acquisition of quoted shares         (35,854)         (25,395)           Dividend income received         534         2,835           Finance income received         2,316         911	Biological assets	(775)	-
Finance costs paid         (38,635)         (45,215)           Net taxes paid         (9,210)         (25,957)           Net cash used in operating activities         (62,545)         (92,302)           Cash flows from investing activities         Variable of property, plant and equipment         (1,722)         (6,288)           Purchase of investment properties         (3,345)         (1,718)           Addition of right-of-use assets         (1,181)         (495)           Proceeds from disposal of quoted shares         40,046         49,497           Proceeds from disposal of property, plant and equipment         -         23           Acquisition of quoted shares         (35,854)         (25,395)           Dividend income received         534         2,835           Finance income received         2,316         911	Trade and other payables	60,023	89,537
Net taxes paid         (9,210)         (25,957)           Net cash used in operating activities         (62,545)         (92,302)           Cash flows from investing activities         Variable of property, plant and equipment         (1,722)         (6,288)           Purchase of investment properties         (3,345)         (1,718)           Addition of right-of-use assets         (1,181)         (495)           Proceeds from disposal of quoted shares         40,046         49,497           Proceeds from disposal of property, plant and equipment         -         23           Acquisition of quoted shares         (35,854)         (25,395)           Dividend income received         534         2,835           Finance income received         2,316         911	Cash used in operations	(14,700)	(21,130)
Net cash used in operating activities         (62,545)         (92,302)           Cash flows from investing activities         (1,722)         (6,288)           Purchase of property, plant and equipment         (1,722)         (6,288)           Purchase of investment properties         (3,345)         (1,718)           Addition of right-of-use assets         (1,181)         (495)           Proceeds from disposal of quoted shares         40,046         49,497           Proceeds from disposal of property, plant and equipment         -         23           Acquisition of quoted shares         (35,854)         (25,395)           Dividend income received         534         2,835           Finance income received         2,316         911	Finance costs paid	(38,635)	(45,215)
Cash flows from investing activitiesPurchase of property, plant and equipment(1,722)(6,288)Purchase of investment properties(3,345)(1,718)Addition of right-of-use assets(1,181)(495)Proceeds from disposal of quoted shares40,04649,497Proceeds from disposal of property, plant and equipment-23Acquisition of quoted shares(35,854)(25,395)Dividend income received5342,835Finance income received2,316911	Net taxes paid	(9,210)	(25,957)
Purchase of property, plant and equipment       (1,722)       (6,288)         Purchase of investment properties       (3,345)       (1,718)         Addition of right-of-use assets       (1,181)       (495)         Proceeds from disposal of quoted shares       40,046       49,497         Proceeds from disposal of property, plant and equipment       -       23         Acquisition of quoted shares       (35,854)       (25,395)         Dividend income received       534       2,835         Finance income received       2,316       911	Net cash used in operating activities	(62,545)	(92,302)
Purchase of investment properties       (3,345)       (1,718)         Addition of right-of-use assets       (1,181)       (495)         Proceeds from disposal of quoted shares       40,046       49,497         Proceeds from disposal of property, plant and equipment       -       23         Acquisition of quoted shares       (35,854)       (25,395)         Dividend income received       534       2,835         Finance income received       2,316       911	Cash flows from investing activities		
Addition of right-of-use assets       (1,181)       (495)         Proceeds from disposal of quoted shares       40,046       49,497         Proceeds from disposal of property, plant and equipment       -       23         Acquisition of quoted shares       (35,854)       (25,395)         Dividend income received       534       2,835         Finance income received       2,316       911	Purchase of property, plant and equipment	(1,722)	(6,288)
Proceeds from disposal of quoted shares 40,046 49,497 Proceeds from disposal of property, plant and equipment 40,046 49,497 Proceeds from disposal of property, plant and equipment 40,046 49,497 23 Acquisition of quoted shares (35,854) Dividend income received 534 2,835 Finance income received 911	Purchase of investment properties	(3,345)	(1,718)
Proceeds from disposal of property, plant and equipment  Acquisition of quoted shares  Dividend income received  Finance income received  123  (25,395)  2,835  Finance income received  2,316  911	Addition of right-of-use assets		, ,
Acquisition of quoted shares       (35,854)       (25,395)         Dividend income received       534       2,835         Finance income received       2,316       911	Proceeds from disposal of quoted shares	40,046	49,497
Acquisition of quoted shares       (35,854)       (25,395)         Dividend income received       534       2,835         Finance income received       2,316       911	Proceeds from disposal of property, plant and equipment		
Dividend income received         534         2,835           Finance income received         2,316         911		(35,854)	(25,395)
Finance income received 2,316 911	·	• • •	, ,
Net cash generated from investing activities 794 19,370	Finance income received	2,316	
	Net cash generated from investing activities	794	19,370



### INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

### UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Cash flows from financing activities         403/2022         31/03/2022         RM'000           Payment of borrowing costs         (2,282)         (10)           Drawdown from borrowings         101,637         130,254           Repayment of borrowings         (144,570)         (46,125)           Repayment of principal portion of lease liabilities         (956)         (705)           Placement of debt service reserve, escrow accounts and deposits         (51,494)         (18,755)           Proceeds from issuance of shares to non-controlling interests         (4,900)         -           Purchase of treasury shares         (160)         (4,549)           Perpetual bond distribution paid         (17,350)         (8,609)           Net cash (used in)/generated from financing activities         (120,075)         51,501           Net decrease in cash and cash equivalents         (181,826)         (21,431)           Effects of foreign exchange rate changes         117         90           Cash and cash equivalents at beginning of financial period         436,394         404,092           * Cash and cash equivalents at end of financial period*         254,685         382,751           * Cash and bank balances         513,718         619,701           Less: Cash and cash equivalents not available for use         (235,489)			
Cash flows from financing activities Payment of borrowing costs Payment of borrowings Payment of principal portion of lease liabilities Papayment of principal portion of lease liabilities (956) Papayment of portion of lease liabilities (956) (705) Papayment of portion of lease liabilities (51,494) (18,755) Proceeds from issuance of shares to non-controlling interests (4,900) Purchase of treasury shares (160) (4,549) Perpetual bond distribution paid (17,350) (8,609) Perpetual bond distribution paid (17,350) (8,609) Perpetual bond distribution paid (17,350) (8,609) Net cash (used in)/generated from financing activities (181,826) (21,431) Effects of foreign exchange rate changes 117 90 Cash and cash equivalents at beginning of financial period 436,394 404,092 Cash and cash equivalents at end of financial period comprise the following:  * Cash and cash equivalents at end of financial period comprise the following:  Cash and bank balances 513,718 619,701 Less: Cash and cash equivalents not available for use (235,489) (216,943) Less: Bank overdrafts (23,544) (20,007)		31/03/2022	31/03/2021
Payment of borrowing costs         (2,282)         (10)           Drawdown from borrowings         101,637         130,254           Repayment of borrowings         (144,570)         (46,125)           Repayment of principal portion of lease liabilities         (956)         (705)           Placement of debt service reserve, escrow accounts and deposits         (51,494)         (18,755)           Placement of debt service reserve, escrow accounts and deposits         (4,900)         -           with licensed banks not available for use         (51,494)         (18,755)           Proceeds from issuance of shares to non-controlling interests         (4,900)         -           Purchase of treasury shares         (160)         (4,549)           Perpetual bond distribution paid         (17,350)         (8,609)           Net cash (used in)/generated from financing activities         (120,075)         51,501           Net decrease in cash and cash equivalents         (181,826)         (21,431)           Effects of foreign exchange rate changes         117         90           Cash and cash equivalents at beginning of financial period         436,394         404,092           Cash and cash equivalents at end of financial period comprise the following:         513,718         619,701           Less: Cash and cash equivalents not available for use <td></td> <td>RM'000</td> <td>RM'000</td>		RM'000	RM'000
Payment of borrowing costs         (2,282)         (10)           Drawdown from borrowings         101,637         130,254           Repayment of borrowings         (144,570)         (46,125)           Repayment of principal portion of lease liabilities         (956)         (705)           Placement of debt service reserve, escrow accounts and deposits         (51,494)         (18,755)           Placement of debt service reserve, escrow accounts and deposits         (4,900)         -           with licensed banks not available for use         (51,494)         (18,755)           Proceeds from issuance of shares to non-controlling interests         (4,900)         -           Purchase of treasury shares         (160)         (4,549)           Perpetual bond distribution paid         (17,350)         (8,609)           Net cash (used in)/generated from financing activities         (120,075)         51,501           Net decrease in cash and cash equivalents         (181,826)         (21,431)           Effects of foreign exchange rate changes         117         90           Cash and cash equivalents at beginning of financial period         436,394         404,092           Cash and cash equivalents at end of financial period comprise the following:         513,718         619,701           Less: Cash and cash equivalents not available for use <td>Cash flows from financing activities</td> <td></td> <td></td>	Cash flows from financing activities		
Drawdown from borrowings         101,637         130,254           Repayment of borrowings         (144,570)         (46,125)           Repayment of principal portion of lease liabilities         (956)         (705)           Placement of debt service reserve, escrow accounts and deposits with licensed banks not available for use         (51,494)         (18,755)           Proceeds from issuance of shares to non-controlling interests         (4,900)         -           Purchase of treasury shares         (160)         (4,549)           Perpetual bond distribution paid         (17,350)         (8,609)           Net cash (used in)/generated from financing activities         (120,075)         51,501           Net decrease in cash and cash equivalents         (181,826)         (21,431)           Effects of foreign exchange rate changes         117         90           Cash and cash equivalents at beginning of financial period         436,394         404,092           Cash and cash equivalents at end of financial period*         254,685         382,751           * Cash and bank balances         513,718         619,701           Less: Cash and cash equivalents not available for use         (235,489)         (216,943)           Less: Bank overdrafts         (20,007)	•	(2,282)	(10)
Repayment of borrowings (144,570) (46,125) Repayment of principal portion of lease liabilities (956) (705)  Placement of debt service reserve, escrow accounts and deposits with licensed banks not available for use (51,494) (18,755)  Proceeds from issuance of shares to non-controlling interests (4,900) - Purchase of treasury shares (160) (4,549)  Perpetual bond distribution paid (17,350) (8,609)  Net cash (used in)/generated from financing activities (120,075) 51,501  Net decrease in cash and cash equivalents (181,826) (21,431)  Effects of foreign exchange rate changes 117 90  Cash and cash equivalents at beginning of financial period 436,394 404,092  Cash and cash equivalents at end of financial period* 254,685 382,751  * Cash and bank balances 513,718 619,701  Less: Cash and cash equivalents not available for use (235,489) (216,943)  Less: Bank overdrafts (23,544) (20,007)	Drawdown from borrowings	101,637	130,254
Repayment of principal portion of lease liabilities (956) (705)  Placement of debt service reserve, escrow accounts and deposits with licensed banks not available for use (51,494) (18,755)  Proceeds from issuance of shares to non-controlling interests (4,900)  Purchase of treasury shares (160) (4,549)  Perpetual bond distribution paid (17,350) (8,609)  Net cash (used in)/generated from financing activities (120,075) 51,501  Net decrease in cash and cash equivalents (181,826) (21,431)  Effects of foreign exchange rate changes 117 90  Cash and cash equivalents at beginning of financial period 436,394 404,092  Cash and cash equivalents at end of financial period* 254,685 382,751  * Cash and cash equivalents at end of financial period comprise the following:  Cash and bank balances 513,718 619,701  Less: Cash and cash equivalents not available for use (235,489) (216,943)  Less: Bank overdrafts (23,544) (20,007)		(144,570)	(46,125)
Placement of debt service reserve, escrow accounts and deposits with licensed banks not available for use Proceeds from issuance of shares to non-controlling interests (4,900) Purchase of treasury shares (160) Perpetual bond distribution paid (17,350) Ret cash (used in)/generated from financing activities (120,075)  Net decrease in cash and cash equivalents (181,826) Effects of foreign exchange rate changes 117 90 Cash and cash equivalents at beginning of financial period Cash and cash equivalents at end of financial period*  * Cash and cash equivalents at end of financial period comprise the following:  Cash and bank balances Less: Cash and cash equivalents not available for use (235,489) Less: Bank overdrafts (18,755) (160) (4,549) (17,350) (18,609) (17,350) (18,609) (120,075) (120,075) (120,075) (121,431) (21,431) (21,431) (21,431) (22,431) (23,544) (20,007)		(956)	, ,
Proceeds from issuance of shares to non-controlling interests Purchase of treasury shares Perpetual bond distribution paid (17,350) (8,609)  Net cash (used in)/generated from financing activities (181,826) Effects of foreign exchange rate changes Tash and cash equivalents at beginning of financial period Cash and cash equivalents at beginning of financial period Cash and cash equivalents at end of financial period*  * Cash and cash equivalents at end of financial period comprise the following:  Cash and bank balances Less: Cash and cash equivalents not available for use Less: Bank overdrafts (181,826) (21,431) (21,431) (21,431) (21,431) (21,431) (21,431) (21,431) (21,431) (21,431) (22,431) (23,489) (23,544) (23,544) (20,007)			, ,
Purchase of treasury shares Perpetual bond distribution paid (17,350) Ret cash (used in)/generated from financing activities (120,075)  Net decrease in cash and cash equivalents Effects of foreign exchange rate changes 117 90 Cash and cash equivalents at beginning of financial period 436,394 Cash and cash equivalents at end of financial period*  * Cash and cash equivalents at end of financial period comprise the following:  Cash and bank balances Cash and cash equivalents not available for use Less: Cash and cash equivalents not available for use Less: Bank overdrafts (160) (4,549) (21,431)	with licensed banks not available for use	(51,494)	(18,755)
Perpetual bond distribution paid (17,350) (8,609)  Net cash (used in)/generated from financing activities (120,075) 51,501  Net decrease in cash and cash equivalents (181,826) (21,431)  Effects of foreign exchange rate changes 117 90  Cash and cash equivalents at beginning of financial period 436,394 404,092  Cash and cash equivalents at end of financial period* 254,685 382,751  * Cash and bank balances 513,718 619,701  Less: Cash and cash equivalents not available for use (235,489) (216,943)  Less: Bank overdrafts (20,007)	Proceeds from issuance of shares to non-controlling interests	(4,900)	· -
Net cash (used in)/generated from financing activities(120,075)51,501Net decrease in cash and cash equivalents(181,826)(21,431)Effects of foreign exchange rate changes11790Cash and cash equivalents at beginning of financial period436,394404,092Cash and cash equivalents at end of financial period*254,685382,751* Cash and cash equivalents at end of financial period comprise the following:Cash and bank balances513,718619,701Less: Cash and cash equivalents not available for use(235,489)(216,943)Less: Bank overdrafts(23,544)(20,007)	Purchase of treasury shares	(160)	(4,549)
Net decrease in cash and cash equivalents  Effects of foreign exchange rate changes  Cash and cash equivalents at beginning of financial period  * Cash and cash equivalents at end of financial period*  * Cash and cash equivalents at end of financial period comprise the following:  Cash and bank balances  Cash and bank balances  Less: Cash and cash equivalents not available for use  Less: Bank overdrafts  (181,826)  (21,431)  90  436,394  404,092  254,685  382,751  * 619,701  Less: Cash and cash equivalents not available for use  (235,489)  (216,943)  (20,007)	Perpetual bond distribution paid	(17,350)	(8,609)
Effects of foreign exchange rate changes  Cash and cash equivalents at beginning of financial period  Cash and cash equivalents at end of financial period*  * Cash and cash equivalents at end of financial period comprise the following:  Cash and bank balances  Cash and bank balances  Less: Cash and cash equivalents not available for use  Less: Bank overdrafts  117  90  436,394  404,092  254,685  382,751  * 619,701  Less: Cash and cash equivalents not available for use  (235,489)  (216,943)  (20,007)	Net cash (used in)/generated from financing activities	(120,075)	51,501
Effects of foreign exchange rate changes  Cash and cash equivalents at beginning of financial period  Cash and cash equivalents at end of financial period*  * Cash and cash equivalents at end of financial period comprise the following:  Cash and bank balances  Cash and bank balances  Less: Cash and cash equivalents not available for use  Less: Bank overdrafts  117  90  436,394  404,092  254,685  382,751  * 619,701  Less: Cash and cash equivalents not available for use  (235,489)  (216,943)  (20,007)	Net decrease in cash and cash equivalents	(181,826)	(21,431)
Cash and cash equivalents at beginning of financial period Cash and cash equivalents at end of financial period*  * Cash and cash equivalents at end of financial period comprise the following:  Cash and bank balances Cash and bank balances Less: Cash and cash equivalents not available for use Less: Bank overdrafts  436,394 404,092 382,751  * Cash and cash equivalents at end of financial period comprise the following:  (216,943) (216,943) (20,007)	·	•	, ,
* Cash and cash equivalents at end of financial period*  * Cash and cash equivalents at end of financial period comprise the following:  Cash and bank balances Less: Cash and cash equivalents not available for use Less: Bank overdrafts  254,685 382,751 619,701 (216,943) (216,943) (220,007)		436,394	404,092
Cash and bank balances       513,718       619,701         Less: Cash and cash equivalents not available for use       (235,489)       (216,943)         Less: Bank overdrafts       (23,544)       (20,007)			
Less: Cash and cash equivalents not available for use(235,489)(216,943)Less: Bank overdrafts(23,544)(20,007)	* Cash and cash equivalents at end of financial period comprise the following:		
Less: Bank overdrafts (23,544) (20,007)	Cash and bank balances	513,718	619,701
Less: Bank overdrafts (23,544) (20,007)	Less: Cash and cash equivalents not available for use	(235,489)	(216,943)
Total cash and cash equivalents at end of financial period 254,685 382,751	Less: Bank overdrafts	(23,544)	, ,
	Total cash and cash equivalents at end of financial period	254,685	382,751



#### INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

# PART A – EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARD ("MFRS") 134

### A1. Basis of preparation

The interim financial statements are unaudited and have been prepared in accordance with the requirements of MFRS 134 Interim Financial Reporting and other MFRSs issued by the Malaysian Accounting Standard Board ("MASB") and paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad.

The interim financial statements should be read in conjunction with the Group's audited consolidated financial statements for the financial year ended 31 December 2021. These explanatory notes attached to the interim financial statements provide an explanation of events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the financial year ended 31 December 2021.

### A2. Changes in accounting policies arising from adoption of new standards, amendments and interpretations

The accounting policies adopted for the interim financial statements are consistent with those of the audited financial statements for the financial year ended 31 December 2021 except for the adoption of the following new amendments to MFRSs:

### Effective for financial periods beginning on or after 1 January 2022:

Amendments to MFRS 1	First-time Adoption of MFRS-Subsidiary as a First-time Adopter
Amendments to MFRS 3	Reference to the Conceptual Framework
Amendments to MFRS 9	Financial Instruments-Fees in the '10 per cent' Test for
	Derecognition of Financial Liabilities
Amendments to MFRS 116	Property, Plant and Equipment-Proceeds before Intended Use
Amendments to MFRS 137	Onerous Contracts-Cost of Fulfilling a Contract
Amendments to MFRS 141	Agriculture-Taxation in Fair Value Measurements

The adoption of the above amendments to MFRSs did not result in material impact to the interim financial statements of the Group.



### INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

### PART A – EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARD ("MFRS") 134

### A2. Changes in accounting policies arising from adoption of new standards, amendments and interpretations (cont'd.)

The followings are new standards, amendments and interpretations that have been issued by the MASB but have not been early adopted by the Group:

### Effective for financial periods beginning on or after 1 January 2023:

MFRS 17*	Insurance Contracts
Amendments to MFRS 17*	Insurance Contracts
Amendments to MFRS 17*	Initial Application of MFRS 17 and MFRS 9-Comparative Information
Amendments to MFRS 101	Classification of Liabilities as Current or Non-current
Amendments to MFRS 101	Disclosure of Accounting Policies
Amendments to MFRS 108	Definition of Accounting Estimates
Amendments to MFRS 112	Deferred Tax related to Assets and Liabilities arising from a Single
	Transaction.

### Effective date deferred to a date to be determined by MASB:

Amendments to MFRS 10 Sale or Contribution of Assets between an Investor and its Associate or Joint Venture

### A3. Comments about seasonal or cyclical factors

The business operations of the Group were not significantly affected by any seasonal or cyclical factors.

### A4. Nature and amount of items affecting assets, liabilities, equity, net income or cash flows that is unusual because of their nature, size or incidence

There were no unusual items affecting assets, liabilities, equity, net income or cash flows during the financial period under review.

### A5. Material changes in estimates

There were no material changes in estimates for the financial period ended 31 March 2022.

<sup>\*</sup>These standards are not relevant and applicable to the Group.



### INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

## PART A – EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARD ("MFRS") 134

### A6. Debt and equity securities

There were no issuances, cancellations, repurchases, resale and repayments of debt and equity securities for the financial period under review except as follows:

- 1) The Company has repurchased its equity securities of 150,000 ordinary shares at an average price of RM1.07 per share. As at 31 March 2022, the number of treasury shares held was 29,494,743 ordinary shares.
- 2) On 19 January 2022, there was an issuance of 72,000,000 ordinary shares of RM1.20 each pursuant to the conversion of 72,000,000 irredeemable convertible preference shares ("ICPS") to 72,000,000 new ordinary shares by the conversion ratio of 1 unit ICPS to 1 new ordinary share.

### A7. Dividends

No dividend was paid during the current quarter under review.



### INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

# PART A – EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARD ("MFRS") 134

### A8. Segmental information

Segmental information is presented in respect of the Group's principal business segments - property development, property management, property investment, recreation and resort and investment holding and others. The geographical information is not presented as the Group's activities are carried out predominantly in Malaysia.

Business segment analysis for the quarter and financial period ended:

	Property development	Property investment,	Investment	
	•	recreation and	holding and	
Business Segments	management		others	Total
•	RM'000	RM'000	RM'000	RM'000
Individual Quarter/Year To Date				
31 March 2022				
Revenue	152,527	33,723	37,048	223,298
Results from operations	12,667	(702)	(7,501)	4,464
Net finance costs	(14,140)	(12,218)	(17,023)	(43,381)
Share of results of an associate	2,300	-	-	2,300
Share of results of joint ventures	1,115	-	-	1,115
Profit/(loss) before tax	1,942	(12,920)	(24,524)	(35,502)
31 March 2022				
Revenue	185,736	25,199	29,597	240,532
Results from operations	52,997	1,825	(828)	53,994
Net finance costs	(16,347)	(11,663)	(15,686)	(43,696)
Share of results of an associate	8,293	-	-	8,293
Share of results of joint ventures	751	-		751
Profit/(loss) before tax	45,694	(9,838)	(16,514)	19,342



#### INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

# PART A – EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARD ("MFRS") 134

### A9. Material events subsequent to the end of interim period

There were no material events subsequent to the end of the current quarter up to the date of this report that have not been reflected in the interim financial statements under review, except for the following:-

1) On 8 April 2022, there was an issuance of 148,000,000 ordinary shares of RM1.20 each pursuant to the conversion of 148,000,000 ICPS to 148,000,000 new ordinary shares by the conversion ratio of 1 unit ICPS to 1 new ordinary share.

### A10. Changes in composition of the Group

- 1) On 14 January 2022, the Company acquired the balance of 4,900,000 ordinary shares in Tropicana SJII Education Management Sdn Bhd ("TSEM") for a total consideration of RM4,900,000. Following the completion of the acquisition, TSEM has become a wholly-owned subsidiary of the Company.
- 2) On 24 January 2022, the Company divested its 1 ordinary share in Tropicana Property Services Sdn Bhd ("TPSSB") representing 100% of the total paid-up capital, for a total cash consideration of RM1 to Megaxis Sdn Bhd ("MSB"). Accordingly, TPSSB has become a wholly-owned subsidiary of MSB, which in turn is an indirect wholly-owned subsidiary of the Company.
- 3) On 27 January 2022, Tropicana Plaza Sdn Bhd ("TPLSB"), a wholly-owned subsidiary of MSB acquired 84,000 ordinary shares in Mesatria Sdn Bhd ("MSSB") representing 42% of the total paid-up share capital for a total cash consideration of RM783,720.
- 4) On 27 January 2022, Tropicana Paisley Sdn Bhd ("TPSSB"), a wholly-owned subsidiary of MSB acquired 84,042 ordinary shares in Tencomurni Sdn Bhd ("TSB") representing 42% of the total paid-up share capital for a total cash consideration of RM783,720.
- 5) On 27 January 2022, Tropicana Saujana Sdn Bhd ("TSSB"), a wholly-owned subsidiary of MSB acquired 84,000 ordinary shares in Alam Tiasa Sdn Bhd ("ATSB") representing 42% of the total paid-up share capital for a total cash consideration of RM588,840.
- 6) On 14 February 2022, the Company had incorporated a wholly-owned subsidiary, Tropicana Entertainment And Retail Sdn Bhd with 1 ordinary share representing 100% of a total paid-up capital, for a total consideration of RM1.

Save as disclosed above, there were no other changes in the composition of the Group.



### INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

## PART A – EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARD ("MFRS") 134

### A11. Changes in contingent liabilities or contingent assets

Since the last annual audited position as at 31 December 2021, the Group's contingent liabilities have changed due to the decrease of RM37.2million in corporate guarantees (unsecured) issued by the Company to licensed financial institutions for banking facilities granted to the subsidiaries of the Group.

Save as disclosed above, there were no other changes in contingent liabilities of the Group.

### A12. Capital commitments

The amount of commitments for capital expenditure as at 31 March 2022 is as follows:

	As at 31/03/2022 RM'000	As at 31/12/2021 RM'000
Capital expenditure:		
Approved and contracted for:		
- Property, plant and equipment	21,299	18,746
- Investment properties	11,339	14,329
	32,638	33,075
Approved and not contracted for:		
- Investment properties	4,028	2,533
	36,666	35,608



#### INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

### PART B – EXPLANATORY NOTES PURSUANT TO PART A OF APPENDIX 9B OF THE MAIN MARKET LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BHD

### B1. Performance review

For the current quarter under review, the Group recorded revenue of RM223.3 million (Q1 2021: RM240.5 million) which was RM17.2 million or 7.2% lower when compared to the corresponding quarter in the preceding year. The decrease in revenue in the current quarter is mainly contributed by lower progress billings across key projects in the Klang Valley and Southern Region as compared to the corresponding quarter in the preceding year.

The Group recorded a loss before tax of RM35.5 million compared to the profit before tax of RM19.3 million in the corresponding quarter in the preceding year. The loss before tax in the current quarter was mainly attributed to the hotel business which has not fully recovered from the COVID-19 pandemic.

### B2. Variation of results against preceding quarter

The Group's revenue of RM223.3 million in the current quarter was RM40.5 million or 15.3% lower when compared to preceding quarter ended 31 December 2021. This was due to lower sales as compared to preceding quarter where buyers were rushing to sign sales and purchase agreements to take advantage of the incentives under the Home Ownership Campaign ("HOC") before the HOC ended on 31 December 2021. Lower progress billings across projects in the Klang Valley and the Southern Region also resulted in a lower revenue in the current quarter.

The Group's recorded loss before tax of RM35.5 million which was RM55.8 million lower than the preceding quarter ended 31 December 2021 was mainly attributed to the higher sales and marketing expenses due to new project launches in Tropicana Aman, Kota Kemuning and Gelang Patah, Johor Bahru as well as higher general and administrative expenses incurred by the Group as mentioned above.



#### INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

### PART B – EXPLANATORY NOTES PURSUANT TO PART A OF APPENDIX 9B OF THE MAIN MARKET LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BHD

### **B3.** Prospects

The federal government of Malaysia had on 8 March 2022, announced the reopening of its borders from 1 April 2022 onwards to transition to the endemic phase of Covid-19. Thus, it will bring Malaysia's economy back on track for recovery and improve overall business sentiments.

With the reopening of the international borders, the Group believes that there will be demand for properties in prime locations in Tropicana's established, mature and developing townships, with attractive pricing and various promotional packages. Premised on the expected demand, the Group will continue to launch its properties at strategic locations across the Klang Valley, Genting Highlands, Northern Regions and Southern Regions. Moving forward, the Group will also continue to launch new phases in its established development sites, namely Tropicana Heights, Tropicana Aman, Tropicana Metropark and Tropicana Danga Cove.

The Group remains positive and confident on the long-term prospects of its property development business as the Group will continue to develop and market its properties located at various strategic locations, which subsequently are expected to contribute positively to the future earnings of the Group. In addition, the Group believes that its various sales and marketing initiatives will continue to bear fruit and ultimately secure more sales in the coming years.



### INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

# PART B – EXPLANATORY NOTES PURSUANT TO PART A OF APPENDIX 9B OF THE MAIN MARKET LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BHD

### B4. Profit forecast or profit guarantee

No profit forecast or profit guarantee was issued for the financial period.

### B5. Income tax

	Individ	ual Quarter	Year to Date	
	31/03/2022	31/03/2021	31/03/2022	31/03/2021
	RM'000	RM'000	RM'000	RM'000
Tax expense for the period  Over/(under) provision of tax for	(13,699)	(31,277)	(13,699)	(31,277)
previous financial period	6	(692)	6	(692)
Real property gain tax	-	(10)	-	(10)
Deferred tax transfers	23,950	21,012	23,950	21,012
Total Group's tax benefit/(expense)	10,257	(10,967)	10,257	(10,967)

The Group's effective tax rate was higher than the statutory tax rate mainly due to non-allowable expenses for tax deduction.



#### INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

### PART B – EXPLANATORY NOTES PURSUANT TO PART A OF APPENDIX 9B OF THE MAIN MARKET LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BHD

### **B6.** Corporate Proposals

### Status of corporate proposals

The following corporate proposals announced by the Company has not been completed as at 18 May 2022, being the latest practicable date which is not earlier than 7 days from the date of issuance of this interim financial report:

- 1) On 15 April 2013, Tropicana Aman Sdn Bhd ("TASB"), a wholly-owned subsidiary of the Company, entered into a sale and purchase cum development agreement with Menteri Besar Selangor (Pemerbadanan) ("MBI") and Permodalan Negeri Selangor Berhad ("PNSB") for the proposed acquisition cum development of 11 parcels of leasehold land, all in Mukim Tanjong Duabelas, District of Kuala Langat, State of Selangor measuring approximately 1,172.26 acres for a total cash consideration of RM1,297,259,264 ("Proposed Acquisition").
  - MBI, PNSB and TASB had entered into supplementary agreements in respect of the Proposed Acquisition on 7 August 2014 and 12 March 2015 respectively. As at the date of this report, TASB has paid for 19 sub-divided parcels. The acquisitions for 18 sub-divided parcels are completed and TASB is in the midst of completing the transfer process for 1 sub-divided parcel. There are remaining 10 parcels of land to be paid.
- 2) On 1 November 2021 and 5 November 2021, the Company has announced that Tropicana Alam Sdn. Bhd. (formerly known as Tropicana Senibong Sdn Bhd), a wholly-owned subsidiary of the Company, have on 1 November 2021, entered into a joint venture agreement with Puncak Alam Housing Sdn Bhd, a non-related party, to form an unincorporated joint venture for the purpose of developing three parcels of leasehold land, all situated in Mukim of Ijok, District of Kuala Selangor, State of Selangor, having an aggregate area of approximately 362.74 acres.
- 3) On 23 August 2021, the Company has announced that the Company proposes to undertake a proposed private placement of up to 10% of the total number of issued ordinary shares in the Company (excluding treasury shares) ("Tropicana Shares") ("Private Placement"). The Private Placement will be undertaken in accordance with the general mandate pursuant to Sections 75 and 76 of the Companies Act 2016. The Company has completed the issuance of 2,000,000 new Tropicana Shares, being the first tranche of the Private Placement, on 11 October 2021. The Company had on 11 February 2022, made an application to Bursa Securities for an extension of time of 6 months up to 29 August 2022 in which approval was then granted by Bursa Securities on 15 February 2022.



### INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

### PART B – EXPLANATORY NOTES PURSUANT TO PART A OF APPENDIX 9B OF THE MAIN MARKET LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BHD

### B7. Borrowings

·	As at 31/03/2022 RM'000	As at 31/12/2021 RM'000
Secured short term borrowings	548,814	544,636
Secured long term borrowings	3,330,160	3,371,167
	3,878,974	3,915,803

### B8. Material litigation

On 26 August 2013, the Company received an order from the Arbitral Tribunal to add the Company as a party to the arbitration proceedings between Dijaya-Malind JV (Mauritius) Limited ("DMML"), Dijaya-Malind Properties (India) Private Limited ("DMPPL") and Starlite Global Enterprise (India) Limited ("SGEIL") ("Order").

The arbitration proceedings were previously instituted by DMML and DMPPL against SGEIL to seek the return of the deposit sum and damages arising from termination of the Deed of Novation cum Joint Development Agreement.

The Company appealed to the City Civil Court of Hyderabad against the Order which was dismissed on 2 June 2014. As our legal counsel is in the opinion that the Order is erroneous and wrong in law, the Company has filed a further appeal to the High Court of Judicature of Andhra Pradesh and is pending a hearing date to be set.

### B9. Dividend payable

There was no dividend proposed for the guarter under review.



### INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

### PART B – EXPLANATORY NOTES PURSUANT TO PART A OF APPENDIX 9B OF THE MAIN MARKET LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BHD

### B10. (Loss)/ earnings per share

### a) Basic (loss)/earnings per share

Basic earnings/(loss) per ordinary share were calculated by dividing (loss)/profit for the period attributable to owners of the parent by the weighted average number of ordinary shares outstanding during the financial year.

	Individual Quarter		Year to Date	
	31/03/2022	31/03/2021	31/03/2022	31/03/2021
(Loss)/profit attributable to owners of the				
parent (RM'000)	(33,394)	2,344	(33,394)	2,344
Weighted average number of ordinary				
shares ('000)	1,500,586	1,457,575	1,500,586	1,457,575
Basic (loss)/earnings per share (sen)	(2.23)	0.16	(2.23)	0.16

### b) <u>Diluted (loss)/earnings per share</u>

For the purpose of calculating diluted (loss)/earnings per share, the net (loss)/profit for the period attributable to owners of the parent and the weighted average number of ordinary shares and ICPS outstanding during the period have been adjusted for the dilutive effects of all potential ordinary shares.

	Individual Quarter		Year to Date	
	31/03/2022	31/03/2021	31/03/2022	31/03/2021
(Loss)/Profit attributable to owners of the				
parent (RM'000)	(33,394)	2,344	(33,394)	2,344
Weighted average number of ordinary				
shares ('000) for the purpose of diluted				
earnings per share	1,500,586	1,457,575	1,500,586	1,457,575
Effect of conversion of ICPS to				
ordinary shares	924,473	924,473	924,473	924,473
Adjusted weighted average number of				
ordinary shares in issue ('000) for the				
purpose of diluted earnings per share	2,425,059	2,439,961	2,425,059	2,439,961
Diluted (loss)/earnings per share (sen)	(1.38)	0.10	(1.38)	0.10



### INTERIM FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31 MARCH 2022

### PART B – EXPLANATORY NOTES PURSUANT TO PART A OF APPENDIX 9B OF THE MAIN MARKET LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BHD

### B11. Notes to the statements of comprehensive income

Profit for the period/year is arrived at after (crediting)/charging:-	Individual Quarter 31/03/2022 RM'000	Year to Date 31/03/2022 RM'000
, , , , , , , , , , , , , , , , , , , ,	(0.040)	(0.040)
Finance income	(2,316)	(2,316)
Finance costs	45,697	45,697
Amortisation of intangible assets	115	115
Depreciation of property, plant and equipment	8,691	8,691
Depreciation of right-of-use assets	1,412	1,412

### B12. Auditors' report on preceding annual financial statements

The auditors' report of the financial statements for the financial year ended 31 December 2021 was not subject to any qualification.

#### B13. Authorisation for issue

The interim financial statements were authorised for issuance by the Board of Directors in accordance with the Directors' resolution dated 25 May 2022.